(Q53200173)

English

The significant immunological characteristics of peripheral blood neutrophil-to-lymphocyte ratio and Fas ligand expression incidence in nephrectomized tumor in late recurrence from renal cell carcinoma.

scientific article published on 7 December 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/22153754

The significant immunological characteristics of peripheral blood neutrophil-to-lymphocyte ratio and Fas ligand expression incidence in nephrectomized tumor in late recurrence from renal cell carcinoma. (English)

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/22153754

1 reference

based on heuristic

inferred from title

Nobuyuki Hinata

4

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/22153754

author name string

Takehiro Sejima

1

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/22153754

Hideto Iwamoto

2

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/22153754

Shuichi Morizane

3

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/22153754

Akihisa Yao

5

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/22153754

Tadahiro Isoyama

6

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/22153754

Motoaki Saito

7

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/22153754

Atsushi Takenaka

8

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/22153754

publication date

7 December 2011

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/22153754

Urologic Oncology

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/22153754

31

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/22153754

7

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/22153754

1343-1349

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/22153754

The Fas death factor

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.008

7 January 2021

Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.008

7 January 2021

Apoptosis and programmed cell death in immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.008

7 January 2021

Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.008

7 January 2021

Where have all the T cells gone? Mechanisms of immune evasion by tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.008

7 January 2021

Multiple mechanisms of immune evasion can coexist in melanoma tumor cell lines derived from the same patient.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.008

7 January 2021

Antigen presented by tumors in vivo determines the nature of CD8+ T-cell cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.008

7 January 2021

C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.008

7 January 2021

Increased preoperative serum C-reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.008

7 January 2021

Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.008

7 January 2021

The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.008

7 January 2021

Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.008

7 January 2021

Tumor counterattack: fact or fiction?

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.008

7 January 2021

Spontaneous regression of metastatic renal cancer. Case report and literature review

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.008

7 January 2021

Alteration of apoptotic regulatory molecules expression during carcinogenesis and tumor progression of renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.008

7 January 2021

Improving T cell therapy for cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.008

7 January 2021

Human T cell responses against melanoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.008

7 January 2021

Lymphocyte-mediated cytotoxicity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.008

7 January 2021

The "Fas counterattack" is not an active mode of tumor immune evasion in colorectal cancer with high-level microsatellite instability.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.008

7 January 2021

Fas ligand promotes tumor immune evasion of colon cancer in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.008

7 January 2021

The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.008

7 January 2021

CD95's deadly mission in the immune system

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.008

7 January 2021

Fas Ligand Expression in Metastatic Renal Cell Carcinoma During Interleukin-2 Based Immunotherapy: No In vivo Effect of Fas Ligand Tumor Counterattack

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.008

7 January 2021

Cancer-related inflammation

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.008

7 January 2021

Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in patients with nonmetastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.008

7 January 2021

Metastatic renal carcinoma comprehensive prognostic system

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.008

7 January 2021

Lymphocyte counts independently predict overall survival in advanced cancer patients: a biomarker for IL-2 immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.008

7 January 2021

Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.008

7 January 2021

Identifiers

10.1016/J.UROLONC.2011.09.008

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/22153754

1 reference

Europe PubMed Central

12 May 2018

http://europepmc.org/abstract/MED/22153754

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53200173&oldid=1368867094"